Breast Cancer, Tinterri (Humanitas): "Genomic Test Since Biopsy"
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.8 Articles
8 Articles
Il Tempo
Milan, 9 Sep. (Adnkronos Salute) - "Running a genomic test directly on the biopsy will get all the benefits of a preventive chemotherapy treatment, probably avoiding much more demolitive interventions. Today this is not yet allowed because it lacks the refundability of the exam." Thus Corrado Tinterri, professor of General Surgery at Humanitas University and responsible for the Humanitas Humanitas Cancer Center Humanitas Humanitas Unit, Rozzano,…
Having the possibility to perform the genomic test in pre-operative phase in patients with locally advanced breast cancer would allow to understand if the tumor responds to chemotherapy. In these cases, using chemotherapy before surgery would allow to avoid much more demolitive surgeries. Today this is not yet allowed because the reducibility of the exam is lacking. It is stated by Corrado Tinterri, professor of General Surgery Humanitas Univers…
(Adnkronos) "Running a genomic test directly on the biopsy will get all the benefits of a preventive chemotherapy treatment, probably avoiding much more demolitive interventions. Today this is not yet allowed because it lacks the refundability of the exam." Thus Corrado Tinterri, professor of General Surgery at Humanitas University and in charge of Humanitas Cancer Breast Unit Senology [...]
notizie.it
Rec News | Lontani dal mainstream(Adnkronos) - “By performing a genomic test directly on the biopsy, all the benefits of preventive chemotherapy would be obtained, avoiding
Coverage Details
Bias Distribution
- 100% of the sources lean Right
Factuality
To view factuality data please Upgrade to Premium
